RamanaykaRPJCBasnayakeBMTK. Evaluation of red flags minimizes missing serious disease in primary care. J Family Med Prim Care2018; 7: 315–318.
2.
VergaroGAimoABarisonA, et al.Key to early diagnosis of cardiac amyloidosis. Red flags from clinical, laboratory and imaging findings. Eur J Prev Cardiol. Epub Ahead of print 4 October2020; 27: 1806–1815.
3.
MaurerMSSchwartzJHGundapaneniB, et al.Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med2018; 379: 1007–1016.
4.
RubergFLGroganMHannaM, et al.Transthyretin amyloid cardiomyopathy. J Am Coll Cardiol2019; 73: 2872–2891.
5.
TanskanenMPeuralinnaTPolvikoskiT, et al.Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med2008; 40: 232–239.
6.
GillmoreJDMaurerMSFalkRH, et al.Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation2016; 133: 2404–2412.
7.
KyleRATherneauTMRajkumarSV, et al.Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med2006; 354: 1362–1369.
8.
SinghVFalkRDi CarliMF, et al.State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nuc Cardiol2019; 26: 158–173.
9.
BrahmanadamVMcGrawSMirzaO, et al.Regression of cardiac amyloidosis after stem cell transplantation assessed by cardiovascular magnetic resonance imaging. Circulation2014; 129: 2326–2328.
